Drug stopping sits at the center of this dementia and brain health question.
The drug that first proved it could stop the deadly cytokine storm in severe COVID-19 was dexamethasone, a cheap, widely available corticosteroid that has been around for decades. In the landmark RECOVERY trial, which enrolled 6,425 patients, dexamethasone 6 mg per day for up to ten days reduced 28-day mortality by roughly 35 percent in mechanically ventilated patients and about 20 percent in those on supplemental oxygen. That single finding, published in the New England Journal of Medicine in 2020, changed the trajectory of the pandemic and remains the foundation of treatment for severe COVID-19 today. But dexamethasone did not turn out to be the only weapon against cytokine storm.
Two other drugs, tocilizumab and baricitinib, earned their own FDA approvals for hospitalized COVID-19 patients by targeting specific nodes in the inflammatory cascade. All three are still actively recommended by the World Health Organization and the National Institutes of Health as of the most recent guidelines updated in August 2025. For anyone caring for a loved one with dementia or another condition that raises vulnerability to severe respiratory infections, understanding these treatments matters. This article covers how each drug works, who benefits most, what the limitations are, and why these therapies remain relevant years after their initial deployment.
Table of Contents
- What Is Cytokine Storm and Why Does It Still Kill COVID-19 Patients?
- Tocilizumab — The IL-6 Blocker That Earned Full FDA Approval
- Baricitinib — The Oral JAK Inhibitor With a Dual Mechanism
- Who Benefits and Who Does Not — Understanding the Treatment Window
- Risks, Side Effects, and What Caregivers Should Watch For
- Why Brain Health Advocates Should Pay Attention to Cytokine Research
- What the Future Holds for Anti-Cytokine Therapies
- Conclusion
- Frequently Asked Questions
What Is Cytokine Storm and Why Does It Still Kill COVID-19 Patients?
Cytokine storm is the term for what happens when the immune system overshoots its response to an infection and begins attacking the body’s own tissues. In severe COVID-19, the virus triggers a flood of pro-inflammatory signaling molecules, including interleukin-6, tumor necrosis factor, and various chemokines, that damage the lungs, blood vessels, and organs far beyond where the virus itself has spread. It is not the virus that kills most critically ill patients. It is their own immune response. this matters enormously for older adults and people living with dementia. Age-related immune dysregulation makes cytokine storm more likely, and the brain is not spared from its effects.
Systemic inflammation can worsen cognitive decline, trigger delirium, and accelerate neurodegenerative processes that were already underway. A patient with Alzheimer’s disease who survives a bout of severe COVID-19 may emerge with measurably worse cognition, in part because of the inflammatory damage that cytokine storm inflicts on the central nervous system. The reason dexamethasone works is blunt but effective. It broadly suppresses the immune system by decreasing gene transcription of the pro-inflammatory cytokines, chemokines, and adhesion molecules that drive the storm. Think of it as turning down the volume on the entire immune response rather than targeting a single instrument. That broad action is both its strength and its limitation, which is why more targeted drugs were needed alongside it.
Tocilizumab — The IL-6 Blocker That Earned Full FDA Approval
Tocilizumab, sold under the brand name Actemra, was originally developed for rheumatoid arthritis. It works by blocking the receptor for interleukin-6, one of the key cytokines that drives the hyperinflammatory cascade in severe COVID-19. The FDA granted it emergency use authorization on June 24, 2021, for hospitalized adults and pediatric patients aged two and older who were already receiving corticosteroids and required supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation. By December 2022, tocilizumab had earned full FDA approval, making it the first monoclonal antibody formally approved for COVID-19 treatment. The numbers from the RECOVERY trial tell a meaningful story. Estimated 28-day mortality was 30.7 percent with tocilizumab compared to 34.9 percent with usual care alone.
Perhaps more striking for patients and families, the median time to hospital discharge was 19 days with tocilizumab versus more than 28 days without it. For a person with dementia, those extra days in the hospital carry their own serious risks, including delirium, falls, loss of routine, and accelerated cognitive decline from the unfamiliar environment. However, tocilizumab is not a standalone therapy. The WHO recommends it specifically for severe and critical COVID-19 patients who have elevated inflammatory markers such as C-reactive protein, and always in combination with corticosteroids like dexamethasone. Giving tocilizumab without corticosteroids has not shown clear benefit. There is also a practical limitation: tocilizumab is an intravenous infusion that requires hospital administration, and during surges it has faced supply shortages that left some hospitals rationing doses.
Baricitinib — The Oral JAK Inhibitor With a Dual Mechanism
Baricitinib, marketed as Olumiant by Eli Lilly, took a different path to approval and brought a distinct advantage. In May 2022, the FDA approved it for hospitalized adults requiring supplemental oxygen, mechanical ventilation, or ECMO, making it the first approved immunomodulatory treatment for COVID-19. It also holds an emergency use authorization for pediatric patients aged two to seventeen. Nearly one million COVID-19 patients worldwide have been treated with baricitinib to date. What makes baricitinib particularly interesting is its dual mechanism. It blocks Janus kinase signaling, a pathway that multiple inflammatory cytokines depend on, which dampens the storm.
But research also suggests it may inhibit viral cell entry by blocking a process called NAK-mediated endocytosis, the cellular machinery the virus co-opts to get inside cells. In a clinical trial of 1,033 patients, those who received baricitinib plus remdesivir had a median recovery time of seven days compared to eight days with placebo plus remdesivir, and all-cause mortality dropped from 13.1 percent to 8.1 percent. For caregivers and families, one practical detail stands out. When researchers compared baricitinib head-to-head with tocilizumab, there was no significant difference in 28-day mortality, but baricitinib showed fewer adverse effects. It is also an oral medication, which can simplify administration in certain clinical settings. The WHO now strongly recommends baricitinib plus corticosteroids for severely and critically ill patients, placing it alongside tocilizumab as a preferred immunomodulatory option.
Who Benefits and Who Does Not — Understanding the Treatment Window
One of the most important findings from the dexamethasone trials was not about who the drug helped but about who it did not. In the RECOVERY trial, patients who were not yet requiring respiratory support showed no benefit from dexamethasone. The results were actually consistent with possible harm in that subgroup. This finding underscores a critical principle: these drugs fight the immune system’s overreaction, not the virus itself. If the immune system has not yet gone into overdrive, suppressing it can leave the patient more vulnerable. This creates a treatment window that clinicians must navigate carefully.
The right time to start corticosteroids and add tocilizumab or baricitinib is when the patient is deteriorating, requiring oxygen, and showing signs of systemic inflammation, such as rising C-reactive protein levels. Starting too early risks suppressing the immune response that the body needs to clear the virus. Starting too late means the inflammatory damage may already be irreversible. For older adults with dementia, this window is especially tricky. Cognitive impairment can mask early symptoms of deterioration. A person who cannot clearly articulate increasing breathlessness or confusion may progress further before anyone recognizes the severity. Caregivers who know their loved one’s baseline behavior are often the first to notice subtle changes, such as increased agitation, refusal to eat, or unusual drowsiness, that signal something beyond the expected course of a mild infection.
Risks, Side Effects, and What Caregivers Should Watch For
Immunosuppressive therapies are not without risk, particularly in a population already vulnerable to infection. Dexamethasone can cause hyperglycemia, which requires monitoring in diabetic patients, and prolonged use raises the risk of secondary infections, including fungal infections. During the pandemic, a devastating wave of mucormycosis, sometimes called black fungus, swept through parts of India, linked in part to steroid overuse in COVID-19 treatment. Tocilizumab carries risks of secondary bacterial infections, gastrointestinal perforation in rare cases, and hepatotoxicity. Clinicians monitor liver function before and during treatment. Baricitinib, while generally associated with fewer adverse effects in COVID-19 trials, can increase the risk of blood clots and herpes zoster reactivation.
For someone with dementia who may already be on multiple medications, the interaction profile of any new drug demands careful review. A warning for families: these drugs are hospital-level treatments, not outpatient prescriptions for early COVID-19. No one should be requesting dexamethasone, tocilizumab, or baricitinib for a mild case managed at home. Their benefit is specific to the severe and critical stages of disease, when the cytokine storm is the primary threat. Using them outside that context does not just fail to help. It can actively cause harm.
Why Brain Health Advocates Should Pay Attention to Cytokine Research
The same inflammatory pathways that cytokine storm activates in severe COVID-19 are increasingly implicated in neurodegenerative diseases. Interleukin-6, the cytokine that tocilizumab blocks, is found at elevated levels in the cerebrospinal fluid of patients with Alzheimer’s disease. JAK-STAT signaling, the pathway baricitinib inhibits, plays a role in neuroinflammation and microglial activation in the aging brain.
Researchers are now investigating whether drugs developed for acute cytokine storm might have applications in chronic neuroinflammatory conditions, though this work remains in early stages. For the dementia care community, the broader lesson from COVID-19 cytokine storm treatment is that inflammation is not just a byproduct of disease. It is a driver of tissue damage, including in the brain. Every severe infection that triggers systemic inflammation is a potential insult to cognitive health, which makes preventing severe COVID-19 through vaccination and early treatment all the more important for people already living with or at risk for dementia.
What the Future Holds for Anti-Cytokine Therapies
Current WHO guidelines, updated in August 2025, continue to strongly recommend corticosteroids for severe and critical COVID-19, with IL-6 inhibitors like tocilizumab or JAK inhibitors like baricitinib added for patients with elevated inflammatory markers. These recommendations have remained stable because the evidence base is robust and no superior alternatives have emerged for this specific clinical scenario. The Infectious Diseases Society of America echoes these guidelines in its own living treatment recommendations.
Looking ahead, the experience with COVID-19 cytokine storm has accelerated interest in precision immunomodulation for a range of conditions, from sepsis to autoimmune flares to post-surgical inflammation. The framework of identifying which patients are in cytokine storm, intervening with targeted therapies at the right moment, and combining drugs that work through complementary mechanisms is a model that extends well beyond one pandemic. For families navigating dementia care, the practical takeaway is straightforward: these treatments exist, they work, and they are available in hospitals today should a severe COVID-19 infection occur.
Conclusion
Dexamethasone, tocilizumab, and baricitinib represent three layers of defense against the cytokine storm that makes severe COVID-19 lethal. Dexamethasone remains the universal foundation, recommended for all critically ill patients with respiratory failure. Tocilizumab and baricitinib are added when inflammatory markers are elevated and disease is progressing, each offering a more targeted approach to shutting down the immune overreaction. All three remain in active clinical use and are endorsed by WHO and NIH guidelines current through 2025 and 2026.
For caregivers of people with dementia, the relevance is both immediate and long-term. Immediate, because knowing these treatments exist can inform conversations with hospital teams if a loved one is admitted with severe COVID-19. Long-term, because the inflammatory pathways these drugs target are the same ones implicated in neurodegeneration. Protecting the brain means taking systemic inflammation seriously, whether it comes from a viral infection, a chronic condition, or the slow-burning neuroinflammation that accompanies cognitive decline. Prevention remains the best strategy, but when prevention fails, effective treatments are still available.
Frequently Asked Questions
Q1: Is dexamethasone safe for elderly patients with dementia who get severe COVID-19?
A1: Yes, dexamethasone is recommended for all critically ill COVID-19 patients regardless of age or dementia status, provided they require respiratory support. However, it can cause hyperglycemia and increase infection risk, so blood sugar and signs of secondary infection should be monitored closely. The RECOVERY trial included older adults and the mortality benefit was consistent across age groups for those needing oxygen or ventilation.
Q2: Can these drugs be used at home for early COVID-19 symptoms?
A2: No. Dexamethasone, tocilizumab, and baricitinib are specifically indicated for hospitalized patients with severe or critical COVID-19 requiring supplemental oxygen or ventilation. The RECOVERY trial found no benefit, and possible harm, from dexamethasone in patients who did not need respiratory support. Early COVID-19 is managed with antivirals like nirmatrelvir-ritonavir, not immunosuppressants.
Q3: What is the difference between tocilizumab and baricitinib for COVID-19?
A3: Tocilizumab is an intravenous monoclonal antibody that blocks the IL-6 receptor, while baricitinib is an oral JAK inhibitor that blocks signaling from multiple cytokines. Clinical comparisons show no significant difference in 28-day mortality, but baricitinib has been associated with fewer adverse effects. Both are recommended by WHO for use alongside corticosteroids in patients with elevated inflammatory markers.
Q4: Are these COVID-19 treatments still being used in 2026?
A4: Yes. As of the WHO’s August 2025 guideline update, corticosteroids remain strongly recommended for severe and critical COVID-19, and both tocilizumab and baricitinib are recommended add-on therapies. These drugs are used whenever severe COVID-19 with cytokine storm features presents in hospitals worldwide.
Q5: Does cytokine storm from COVID-19 cause lasting brain damage?
A5: Systemic inflammation from cytokine storm can cross the blood-brain barrier and worsen neuroinflammation, potentially accelerating cognitive decline in people with existing neurodegenerative conditions. Research has documented worse cognitive outcomes in COVID-19 survivors who experienced severe disease, though separating the effects of cytokine storm from other factors like prolonged hospitalization, hypoxia, and sedation remains an active area of study.
You Might Also Like
- Why Doctors Are Re-Examining Every Drug Women Take After Menopause
- The Migraine Drug That Worked in 2 Hours in 80% of Patients
- The Inhaled Drug That Clears Mucus in Cystic Fibrosis Lungs
For more, see NIH MedlinePlus — dementia.
